TRIARYLPYRIDINE COMPOUNDS AND USE THEREOF FOR TREATING CANCER

The invention relates to new bis-triazole 2,4,6-triarylpyridines compounds and their use in the field of oncology, in particular in the prevention and/or treatment of cancer disease. The inventors have observed that the new bis-triazole 2,4,6-triarylpyridines were able to induce cancer cells death either as a standalone or, synergistically, in combination with a lysosomotropic agent, such as chloroquine. The compounds were active against a variety of cancer cells such as HeLa (cervical cancer cell), A549 (lung carcinoma), and PDX-2 or PDX-3 (lung adenocarcinoma). The invention also relates to compositions and methods for prevention and/or treatment of cancer diseases using the new bis-triazole 2,4,6-triarylpyridines compounds..

Medienart:

Patent

Erscheinungsjahr:

2021

Erschienen:

2021

Enthalten in:

Europäisches Patentamt - (2021) vom: 02. Dez. Zur Gesamtaufnahme - year:2021

Sprache:

Englisch

Beteiligte Personen:

BEAUVARLET JENNIFER [VerfasserIn]
DJAVAHERI-MERGNY MOJGAN [VerfasserIn]
RABINDRA NATH DAS [VerfasserIn]
MERGNY JEAN-LOUIS [VerfasserIn]
GUILLON JEAN [VerfasserIn]

Links:

Volltext [kostenfrei]

Themen:

Sonstige Themen:
615
A61K: Preparations for medical, dental, or toilet purpose (...)
A61P: Specific therapeutic activity of chemical compounds (...)
C07D: Heterocyclic compounds (macromolecular compounds c0 (...)
che

Anmerkungen:

Source: www.epo.org (no modifications made), First posted: 2021-12-02, Last update posted on www.tib.eu: 2023-07-19, Last updated: 2023-07-28

Patentnummer:

WO2021239976

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

EPA012582778